On October 31, 2024, we will be updating our current Terms of Use and Privacy Notice. By continuing to use our products and service on October 31, 2024, you are agreeing to our updated Terms of Use and are acknowledging our updated Privacy Notice.
Molly McElwee-Malloy, Harsimran Singh, Haidee Sanchez, Michelle Manning, Steph Habif
To assess satisfaction and trust related to different insulin delivery devices (IDD) in people with type 1 diabetes (T1D) before and after starting Basal-IQ® technology on the t:slim X2™ insulin pump.
Participants completed an online baseline survey including questions about their IDD (prior to Basal-IQ technology). This survey was repeated after 6 months (Post-Assessment) to assess participants’ experience with Basal-IQ technology. Participants elaborated on their experiences with their IDD in open-ended items on satisfaction and trust with their devices.
Overall, there was a significant increase in both satisfaction and trust related to insulin delivery device after 6 months of Basal‑IQ technology use (p<0.001). Although a significant increase in IDD satisfaction was seen across participants (irrespective of Previous IDD type) at Post- Assessment, those on multiple daily injections (MDI) reported the largest increase in satisfaction (4.8 to 9.2, 91% increase), followed by previous Medtronic users (6.3 to 8.6, 36% increase). Previous MDI, OmniPod, and Medtronic users all showed a significant increase in IDD trust at Post-Assessment.
This study demonstrated notable improvements in IDD-related satisfaction and trust after 6 months of Basal-IQ technology use.